Abstract
Protein tyrosine phosphatases (PTPs) are considered to be involved in the etiology of diabetes mellitus, neural diseases such as Alzheimers and Parkinsons disease, regulation of allergy and inflammation, or they are even considered to be responsible for the pathogens` virulence in vivo. Since discovery of first PTP inhibitors such as dephostatin in early 90th years, the research moved on toward search for inhibitors specific for the individual PTP molecules. Currently, dozens of new PTP inhibitors are reported each year, ranging from natural products, natural product analogs, peptides, phosphonates, nonpeptidic inhibitors, mimotopes, metalcontaining inhibitors, redox inhibitors, to simply silencing RNAs as widely used inhibitors of PTP expression. Several currently used drugs also show PTP inhibitory activity. Among them are sodium stibogluconate, phenylarsine oxide, alendronate, etidronate, vanadate, gallium nitrate, suramin, or aplidin. However, the market is still waiting for the first clinically approved selective PTP inhibitor. Here in this review are described inhibitors of activity or expression of the particular classical PTPs, with emphasis on specific inhibition of the respective PTP over the others. The inhibitors are not classified according to their chemical composition, but according to their biological activity, which should help to simplify search for inhibitors of particular classical PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.
Keywords: PTP1B, LAR, SHP-1, SHP-2, CD45, protein tyrosine phosphatase inhibition, cancer, diabetes mellitus
Current Medicinal Chemistry
Title: Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs
Volume: 16 Issue: 6
Author(s): P. Heneberg
Affiliation:
Keywords: PTP1B, LAR, SHP-1, SHP-2, CD45, protein tyrosine phosphatase inhibition, cancer, diabetes mellitus
Abstract: Protein tyrosine phosphatases (PTPs) are considered to be involved in the etiology of diabetes mellitus, neural diseases such as Alzheimers and Parkinsons disease, regulation of allergy and inflammation, or they are even considered to be responsible for the pathogens` virulence in vivo. Since discovery of first PTP inhibitors such as dephostatin in early 90th years, the research moved on toward search for inhibitors specific for the individual PTP molecules. Currently, dozens of new PTP inhibitors are reported each year, ranging from natural products, natural product analogs, peptides, phosphonates, nonpeptidic inhibitors, mimotopes, metalcontaining inhibitors, redox inhibitors, to simply silencing RNAs as widely used inhibitors of PTP expression. Several currently used drugs also show PTP inhibitory activity. Among them are sodium stibogluconate, phenylarsine oxide, alendronate, etidronate, vanadate, gallium nitrate, suramin, or aplidin. However, the market is still waiting for the first clinically approved selective PTP inhibitor. Here in this review are described inhibitors of activity or expression of the particular classical PTPs, with emphasis on specific inhibition of the respective PTP over the others. The inhibitors are not classified according to their chemical composition, but according to their biological activity, which should help to simplify search for inhibitors of particular classical PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.
Export Options
About this article
Cite this article as:
Heneberg P., Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs, Current Medicinal Chemistry 2009; 16 (6) . https://dx.doi.org/10.2174/092986709787458407
DOI https://dx.doi.org/10.2174/092986709787458407 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design A Case-Control Study Investigating the Effect of MTHFR C677T Variant on Performance of Elite Athletes
Endocrine, Metabolic & Immune Disorders - Drug Targets Mango Polyphenols and Its Protective Effects on Diseases Associated to Oxidative Stress
Current Pharmaceutical Biotechnology Magnesium and Anaesthesia
Current Drug Targets Antidiabetic Potential of Silver/Chitosan/Ascorbic Acid Nanocomposites
Current Nanomedicine Islet Cell Transplantation
Current Molecular Medicine Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Subject Index to Volume 1
Current Alzheimer Research Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
Current Medicinal Chemistry Valsartan Protects Against Contrast-Induced Acute Kidney Injury in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Apoptosis
Current Vascular Pharmacology Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Design and Screening Strategies for α-Glucosidase Inhibitors Based on Enzymological Information
Current Topics in Medicinal Chemistry Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes
Current Signal Transduction Therapy Mesenchymal Stem Cell Therapy in Intracerebral Haemorrhagic Stroke
Current Medicinal Chemistry Molecular Mechanisms of Glucocorticoids Action: From Basic Research to Clinical Implications
Current Immunology Reviews (Discontinued) subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders GLP - 1 Analogs: Newer Molecules, Newer Uses
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery